A logo Agilent Technologies +
Agilent Technologies
+

Agilent Technologies (A) Business News

Track Agilent Technologies in real time with a live news feed covering Agilent Technologies stock news, official press releases, company announcements, and an archive of historical Agilent Technologies news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Agilent Technologies, Inc. $A Stock Position Decreased by Assenagon Asset Management S.A.

Defense World

3:45 AM | Saturday | Aug 15, 2026

news photo
Loading...

Assenagon Asset Management S.A. trimmed its stake in Agilent Technologies, Inc. (NYSE: A) by 75.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission.
The fund owned 10,454 shares of the medical research company's stock after selling 31,934 shares during the quarter. Assenagon Asset Management S.A.'s

Read full article redirect
3:45 AM | Saturday | Aug 15, 2026

Agilent Technologies, Inc. $A Stock Position Decreased by Assenagon Asset Management S.A.

Defense World

Assenagon Asset Management S.A. trimmed its stake in Agilent Technologies, Inc. (NYSE: A) by 75.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission.
The fund owned 10,454 shares of the medical research company's stock after selling 31,934 shares during the quarter. Assenagon Asset Management S.A.'s

Read full article arrow
News Thumbnail
3:30 AM | Saturday | Aug 8, 2026

Comparing Agilent Technologies (NYSE:A) & Many Bright Ideas Technologies (OTCMKTS:MBGNF)

Defense World

Agilent Technologies (NYSE: A - Get Free Report) and Many Bright Ideas Technologies (OTCMKTS:MBGNF - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Analyst Recommendations This is a summary

Read full article arrow
News Thumbnail
3:28 AM | Thursday | Jul 30, 2026

Ashton Thomas Securities LLC Buys 6,387 Shares of Agilent Technologies, Inc. $A

Defense World

Ashton Thomas Securities LLC grew its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 47.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,956 shares of the medical research company's stock after acquiring an additional 6,387 shares during

Read full article arrow
News Thumbnail
8:00 AM | Wednesday | Jul 29, 2026

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.

Read full article arrow
News Thumbnail
4:15 PM | Tuesday | Jul 28, 2026

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.
m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo.

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Jul 23, 2026

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.

Read full article arrow
News Thumbnail
3:11 AM | Monday | Jul 20, 2026

Agilent Increases Its Investment in HALO X-ray Technologies

Business Wire

NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.

Read full article arrow
News Thumbnail
11:12 PM | Friday | Jul 17, 2026

Dividend Champion, Contender, And Challenger Highlights: Week Of July 19

Seeking Alpha

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Jul 14, 2026

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.

Read full article arrow
News Thumbnail
2:55 PM | Thursday | Jul 9, 2026

Agilent Strengthens Biopharma Growth Prospects With AI Expansion

Zacks Investment Research

A enhances AI-powered lab software, automation and digital workflows to support drug discovery, biopharma research and long-term growth.

Read full article arrow
News Thumbnail